Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hansa Biopharma AB ( (SE:HNSA) ) has issued an update.
Hansa Biopharma announced that its drug imlifidase successfully met the primary endpoint in a pivotal U.S. Phase 3 trial for kidney transplantation, showing significant improvement in kidney function compared to the control group. The company plans to file a Biologic License Application with the FDA by the end of 2025, potentially enhancing its market position in the U.S. Additionally, Hansa reported a 25.4% increase in year-to-date product sales of IDEFIRIX, reflecting strong market performance. The company also completed a directed share issue raising approximately 671.5 MSEK to support its operational expansion and regulatory submissions.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK32.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma is a commercial-stage biopharmaceutical company based in Lund, Sweden, focusing on developing innovative treatments for rare immunological conditions. The company specializes in a proprietary IgG-cleaving enzyme technology platform, targeting strategic therapeutic areas such as transplantation, autoimmune diseases, gene therapy, and new therapies. Hansa operates in Europe and the U.S., aiming to address unmet medical needs where limited treatment options exist.
Average Trading Volume: 623,785
Technical Sentiment Signal: Sell
Current Market Cap: SEK3.51B
See more data about HNSA stock on TipRanks’ Stock Analysis page.